Stilla Technologies and Promega have established a comarketing agreement and will present data on a new digital polymerase chain reaction (PCR) workflow model at the American Association for Cancer Research (AACR) Annual Meeting on April 10 in New Orleans.
The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.
With this approach, multiplex genomic signatures from liquid biopsies can be generated in decentralized testing away from centralized labs, Stilla and Promega said.
At the AACR meeting, the companies will present data from this liquid biopsy workflow, demonstrating ultrasensitive 32-plex detection from liquid biopsy samples of epidermal growth factor receptor mutations in non-small cell lung cancer, in addition to PIK3CA mutations and human epidermal growth factor receptor 2 amplification in breast cancer, Stilla said.